Melatonina Pharma Nord

Melatonin, the active ingredient in Melatonina Pharma Nord, is a melatonin receptor agonist presented as an oral tablet for oral use. It helps regulate circadian rhythm and promote sleep onset in adults and adolescents with sleep disorders.

GNH USA supplies Melatonina Pharma Nord as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Melatonin acts on melatonin receptors to address disorders of the sleep‑wake cycle.

Insomnia: Improves sleep onset and maintenance in individuals who have difficulty falling or staying asleep. Delayed sleep phase disorder: Helps advance circadian timing and facilitates earlier sleep. Jet lag: Reduces the time required to adjust to new time zones and enhances sleep quality.

Melatonin is generally well tolerated, but some users experience adverse reactions.

Common Side Effects: - Drowsiness or daytime sleepiness - Headache - Dizziness - Nausea - Mild gastrointestinal discomfort - Vivid dreams

Serious or Rare Side Effects: - Allergic reaction (rash, swelling, itching) - Mood changes such as depression or irritability - Hormonal effects including alterations in reproductive hormone levels - Severe hypotension (very low blood pressure) - Rare cases of seizures in predisposed individuals

When considering melatonin therapy, several safety aspects should be reviewed. - Pregnancy: Safety not established; use only if clearly needed. - Breastfeeding: Caution advised; limited data available. - Age: Use lower doses in children; pediatric safety not fully defined. - Drug interactions: Review concomitant medications that affect CYP enzymes. - Medical conditions: Caution in patients with depression or seizure disorders. - Store at ambient temperature: keep in original container, protect from moisture and light.

Melatonin may interact with other medicines; some combinations require avoidance while others need monitoring.

Major Interactions (Avoid): - Anticoagulants: May increase bleeding risk. - Immunosuppressants (e.g., cyclosporine): May reduce melatonin metabolism. - Sedatives: Additive central nervous system depressant effect.

Moderate Interactions (Monitor Closely): - CYP1A2 inhibitors (e.g., fluvoxamine): May increase melatonin plasma levels. - CYP1A2 inducers (e.g., rifampicin): May reduce melatonin efficacy. - Oral contraceptives: May alter melatonin pharmacokinetics.